ERBB2 and breast cancer: Currently, research on PARP inhibitors for adjuvant therapy and neoadjuvant therapy, as well as for the prevention of BC is ongoing, including OlympiA (a phase III study) and GeparSixto study, and in the future, the results of these studies will show evaluating adjuvant therapy with olaparib for HER-2-/gBRCAm BC and exploring the value of a PARP inhibitor in neoadjuvant therapy, respectively.